ES2190205T3 - Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. - Google Patents

Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.

Info

Publication number
ES2190205T3
ES2190205T3 ES99916907T ES99916907T ES2190205T3 ES 2190205 T3 ES2190205 T3 ES 2190205T3 ES 99916907 T ES99916907 T ES 99916907T ES 99916907 T ES99916907 T ES 99916907T ES 2190205 T3 ES2190205 T3 ES 2190205T3
Authority
ES
Spain
Prior art keywords
treatment
nmda receptor
receptor complex
combination
opioid antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99916907T
Other languages
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Philippe Durbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Application granted granted Critical
Publication of ES2190205T3 publication Critical patent/ES2190205T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de una combinación sinérgica de: (i) un antagonista opioide, y (ii) un modulador del complejo receptor NMDA, para la preparación de una composición farmacéutica para el tratamiento de la dependencia del alcohol.
ES99916907T 1998-03-26 1999-03-26 Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. Expired - Lifetime ES2190205T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (en) 1998-03-26 1998-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator

Publications (1)

Publication Number Publication Date
ES2190205T3 true ES2190205T3 (es) 2003-07-16

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99916907T Expired - Lifetime ES2190205T3 (es) 1998-03-26 1999-03-26 Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.

Country Status (17)

Country Link
US (1) US6512009B1 (es)
EP (2) EP0945133A1 (es)
KR (1) KR20010034678A (es)
AT (1) ATE230993T1 (es)
AU (1) AU758569B2 (es)
BR (1) BR9909138A (es)
CA (1) CA2325739C (es)
CZ (1) CZ296367B6 (es)
DE (1) DE69904922T2 (es)
DK (1) DK1063995T3 (es)
ES (1) ES2190205T3 (es)
HU (1) HU226555B1 (es)
NO (1) NO319313B1 (es)
PL (1) PL193241B1 (es)
RU (1) RU2226107C2 (es)
SK (1) SK284623B6 (es)
WO (1) WO1999048500A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913761B1 (en) * 1998-07-20 2005-07-05 Peptech Limited Bioimplant formulation
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
PT2561860T (pt) 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
JP2010513569A (ja) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
WO2009075782A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
ES2430940T3 (es) 2008-02-28 2013-11-22 University Of Virginia Patent Foundation Gen del transportador de serotonina y tratamiento del alcoholismo
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
HUE035574T2 (en) 2010-07-02 2018-05-28 Univ Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
US20240350433A1 (en) * 2021-08-17 2024-10-24 Yale University Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置

Also Published As

Publication number Publication date
EP1063995A1 (en) 2001-01-03
DE69904922T2 (de) 2004-01-08
NO319313B1 (no) 2005-07-11
KR20010034678A (ko) 2001-04-25
ATE230993T1 (de) 2003-02-15
WO1999048500A1 (en) 1999-09-30
HUP0101546A3 (en) 2002-10-28
CA2325739C (en) 2007-05-15
AU758569B2 (en) 2003-03-27
SK284623B6 (sk) 2005-08-04
EP0945133A1 (en) 1999-09-29
PL343069A1 (en) 2001-07-30
RU2226107C2 (ru) 2004-03-27
PL193241B1 (pl) 2007-01-31
SK14282000A3 (sk) 2001-05-10
CA2325739A1 (en) 1999-09-30
BR9909138A (pt) 2000-12-05
AU3522699A (en) 1999-10-18
US6512009B1 (en) 2003-01-28
NO20004788D0 (no) 2000-09-25
HK1032542A1 (en) 2001-07-27
DK1063995T3 (da) 2003-03-10
HUP0101546A2 (hu) 2001-09-28
HU226555B1 (en) 2009-03-30
NO20004788L (no) 2000-11-24
CZ20003525A3 (cs) 2001-04-11
EP1063995B1 (en) 2003-01-15
DE69904922D1 (de) 2003-02-20
CZ296367B6 (cs) 2006-02-15

Similar Documents

Publication Publication Date Title
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
GT199700009A (es) Terapia combinada para la osteoporosis.
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
ATE259658T1 (de) Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten
ES2149044T3 (es) Metanosulfonato de paroxetina.
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
PL343069A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
AR025330A1 (es) Combinacion de sustancias activas con clonidina
ES2173294T3 (es) Nuevo uso medico.
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
UY27753A1 (es) Formulación farmacéutica que comprende melatonina.
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
UY26376A1 (es) Combinaciones sinteticas de un antagonista de nk1 y un analogo estructural de gaba
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
EA200000112A1 (ru) Новая композиция
AR008154A1 (es) Acido (s)-7-[(4,4'-bipiperidin-1-il)carbonil]-2,3,4,5-tetrahidro-4-metil- -3-oxo-1h-1,4-benzodiazepina-2-acetico, como hidrocloruro del mismo, unacomposicion farmaceutica que lo comprende, el uso del mismo y un procedimiento para su preparacion.
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.